In most gliomas from patients carrying POLE/POLD1 germline variants, features of defective polymerase proofreading, e.g. hypermutation, POLE/POLD1-associated mutational signatures, multinucleated cells, and increased intratumoral T cell response, were observed, potentially rendering these tumors sensitive to ICIs. This evidence concerns the gene POLE and central nervous system cancer.